Lycopene used as Anti-inflammatory Nanodrug for the Treatment of Rheumathoid Arthritis: Animal assay, Pharmacokinetics, ABC Transporter and Tissue Deposition.


Journal

Colloids and surfaces. B, Biointerfaces
ISSN: 1873-4367
Titre abrégé: Colloids Surf B Biointerfaces
Pays: Netherlands
ID NLM: 9315133

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 29 08 2019
revised: 06 01 2020
accepted: 18 01 2020
pubmed: 27 1 2020
medline: 24 11 2020
entrez: 27 1 2020
Statut: ppublish

Résumé

Lycopene is a carotenoid drug that has demonstrated several properties, including antioxidant and anti-inflammatory activity. The absorption in human body is very low (10-30 % only). In order to increase the bioavailability, lycopene nanoemulsion was formulated and characterized (atomic force microscopy, thermogravimetric analysis dynamic light scattering and differential scanning calorimetry). Also in vitro assay to evaluate the at-binding with MPR1 was performed. Finally, in vivo assay in animals inducted with rheumathoid arthritis were performed. The results showed that the formulated nanolycopene had superior efficacy when compared with the conventional lycopene (not nano-formulated) in inducted animals (rheumatoid arthritis). The results support the use of nanolycopene as an anti-inflammatory agent for rheumatoid arthritis therapy.

Identifiants

pubmed: 31982791
pii: S0927-7765(20)30044-8
doi: 10.1016/j.colsurfb.2020.110814
pii:
doi:

Substances chimiques

ATP-Binding Cassette Transporters 0
Anti-Inflammatory Agents 0
Zymosan 9010-72-4
Lycopene SB0N2N0WV6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110814

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Vivian Meira Moia (VM)

Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio De Janeiro, Brazil.

Filipe Leal Portilho (F)

Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio De Janeiro, Brazil.

Tatiana Almeida Pádua (T)

Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio De Janeiro, Brazil.

Luana Barbosa Corrêa (L)

Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio De Janeiro, Brazil.

Eduardo Ricci-Junior (E)

Federal University of Rio De Janeiro, College of Pharmacy, Galenical Development Laboratory, Rio De Janeiro, Brazil.

Elaine Cruz Rosas (E)

Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio De Janeiro, Brazil.

Luiciana Magalhaes Rebelo Alencar (L)

Federal University of Maranhão, Department of Physics, Maranhão, Brazil.

Francisco Savio Mendes Sinfronio (F)

Federal University of Maranhão, Department of Electrical Engineering, Maranhão, Brazil.

Angelina Sampson (A)

Department of Chemistry and Biochemistry, College of Natural Sciences, South Dakota State University, Brookings, South Dakota, United States.

Surtaj Hussain Iram (S)

Department of Chemistry and Biochemistry, College of Natural Sciences, South Dakota State University, Brookings, South Dakota, United States.

Frank Alexis (F)

School of Biological Sciences and Engineering, Yachay Tech, San Miguel De Urcuquí, Ecuador.

Maria dasGraccedilasMuller de OliveiraHenriques (MD)

Laboratory of Applied Pharmacology, Farmanguinhos, Oswaldo Cruz Foundation, Rio De Janeiro, Brazil.

Ralph Santos-Oliveira (R)

Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio De Janeiro, Brazil; Zona Oeste State University, Laboratory of Radiopharmacy and Nanoradiopharmaceuticals, Rio De Janeiro, Brazil. Electronic address: roliveira@ien.gov.br.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH